This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.
When developing content for new drug labels, life sciences companies’ regulatory teams face challenges in gathering intelligence to better understand competitive factors, market dynamics, and effective approval strategies. Understanding patient sub-group exceptions for competitive or for label development purposes.
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. The MA pathway is applicable for herbal medicines designed to treat more serious health conditions and require a medical prescription or the supervision of a medical practitioner. 2012/1916).
Pharmaceutical Sales refers to selling prescription and over-the-counter (OTC) medications, medical devices, and other healthcare products to healthcare professionals, or medical providers such as doctors, pharmacists, and hospitals. While not always mandatory, having a degree can enhance your competitiveness.
Generally, entry-level positions offer competitive base salaries with the opportunity to earn significant bonuses or commissions based on performance. Additionally, advanced degrees such as an MBA or specialized certifications can provide a competitive edge in the industry. So, why wait?
Regulation changes, like the introduction of the Prescription Drug Marketing Act in the 1980s, brought about a more structured approach. From social media platforms to e-detailing, the ability to navigate and capitalize on these digital landscapes can give you a significant edge in a competitive market.
On the one hand, patient need for access and business need to restore and accelerate sales and prescription momentum have never been more critical. The challenge is that with the broad adoption of this approach, it is now table stakes—a must-do rather than a competitive advantage.
The laws proposed in several bills range in their potential influence; from restricting the prescription of gender-affirming drugs to criminalising the use of such drugs to allowing states to pursue lawsuits against parents who allow children to access such treatments.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content